Lv21
140 积分 2024-03-08 加入
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
3小时前
已完结
Approvals by the China NMPA in 2023
20天前
已完结
Population Pharmacokinetic Modeling and Exposure–Efficacy and Body Weight–Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma
2个月前
已完结
Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases
2个月前
已完结
Tezepelumab: First Approval
5个月前
已完结
Lebrikizumab: First Approval
5个月前
已完结
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
5个月前
已完结
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis deucravacitinib
8个月前
已完结
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
9个月前
已完结
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
9个月前
已关闭
皖公网安备34019202002308
